The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
April 3, 2023
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
April 3, 2023 (Issue: 1673)
Atezolizumab (Tecentriq – Genentech), an immune
checkpoint inhibitor, has been approved by the FDA
for treatment of unresectable or metastatic alveolar
soft part sarcoma (ASPS) in patients ≥2 years old. It
was previously approved for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.